Molecular Analysis of Gastric and OEsophageal Cancers STudy
Reason given: Never opened to recruitment due to lack of funding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Royal Marsden NHS Foundation Trust
- Trial code
- NCT06702384
- Record updated
- 6 February 2025
- Original description
A prospective translational tissue collection study to identify biomarkers predictive of treatment response/resistance and biomarkers of prognostic value from a series of patients who are investigated for and diagnosed with early or advanced gastric/junctional or oesophageal cancer (oesophagogastric cancer) at The Royal Marsden Hospital.Read full original descriptionShow less
A Prospective Translational Tissue Collection Study in Early and Advanced Gastric and Oesophageal Cancers to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers
A prospective translational tissue collection study to identify biomarkers predictive of treatment response/resistance and biomarkers of prognostic value from a series of patients who are investigated for and diagnosed with early or advanced gastric/junctional or oesophageal cancer (oesophagogastric cancer) at The Royal Marsden Hospital.
Inclusion: Patient is being investigated/treated for OGC at The Royal Marsden Hospital during the study period; Patient has an oesophageal/gastric mass or metastasis amenable to core needle biopsy or surgery; Patient is clinically fit enough to undergo a tumour biopsy or surgery (if not already performed) according to investigator assessment and local guidelines; Patient is ≥ 18 years of age; Patient is able to understand the information provided within the patient information sheet and is able to provide written informed consent; Patient has sufficient tissue for analysis.
Exclusion: Patients who have one or more contraindications to a tumour biopsy or surgery (if not already performed) according to local guidelines; Patients with an uncontrolled concomitant medical condition including, but not limited to, ongoing or active infection not amenable to standard antibiotic therapy, irreversible increased risk of bleeding which prevents biopsy as per standard procedures, or a psychiatric illness or social situation that could affect compliance with study procedures; Patients who have a second active malignancy other than oesophageal/gastric cancer; Patients who are not treated at The Royal Marsden Hospital or referring centre.